Synonyms: Bavencio® | MSB-0010718C | MSB0010718C
avelumab is an approved drug (EMA & FDA (2017))
Compound class:
Antibody
Comment: Avelumab is a programmed death-ligand 1 (PD-L1; CD274) blocking human IgG1 lambda monoclonal antibody . It is the first drug approved for the treatment of Merkel cell carcinoma (MCC).
Peptide sequence and structural information for this antibody are available from its IMGT/mAb-db record. |
Bioactivity Comments |
A patent search identifies that peptide sequences of the heavy and light chains of avelumab are identical to SEQ ID NO: 24 and SEQ ID NO: 25 (respectively) in WO2013079174 A1 [1]. The data in the table below is that proovided for clone A09-246-2, a preferred embodiment of the patent. |
Selectivity at ligand targets | ||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|